Therapies targeting key players of the MAPK pathway such as RAF and MEK have shown encouraging results in thyroid cancers, but less impressive than in melanoma where the MAPK pathway is also at the basis of oncogenesis. Here, RAF1 is linked to thyroid gland carcinoma.